vs
UiPath, Inc.（PATH）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是UiPath, Inc.的1.5倍（$622.0M vs $411.1M），UiPath, Inc.净利率更高（48.4% vs 34.4%，领先13.9%），UiPath, Inc.同比增速更快（15.9% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 0.7%）
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PATH vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.5倍
$411.1M
营收增速更快
PATH
高出11.1%
4.8%
净利率更高
PATH
高出13.9%
34.4%
两年增速更快
RPRX
近两年复合增速
0.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.1M | $622.0M |
| 净利润 | $198.8M | $214.2M |
| 毛利率 | 83.3% | — |
| 营业利润率 | 3.2% | 62.4% |
| 净利率 | 48.4% | 34.4% |
| 营收同比 | 15.9% | 4.8% |
| 净利润同比 | 1966.2% | 2.9% |
| 每股收益（稀释后） | $0.37 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PATHRPRX
| Q4 25 | $411.1M | $622.0M | ||
| Q3 25 | $361.7M | $609.3M | ||
| Q2 25 | $356.6M | $578.7M | ||
| Q1 25 | $423.6M | $568.2M | ||
| Q4 24 | $354.7M | $593.6M | ||
| Q3 24 | $316.3M | $564.7M | ||
| Q2 24 | $335.1M | $537.3M | ||
| Q1 24 | $405.3M | $568.0M |
净利润PATHRPRX
| Q4 25 | $198.8M | $214.2M | ||
| Q3 25 | $1.6M | $288.2M | ||
| Q2 25 | $-22.6M | $30.2M | ||
| Q1 25 | $51.8M | $238.3M | ||
| Q4 24 | $-10.7M | $208.2M | ||
| Q3 24 | $-86.1M | $544.0M | ||
| Q2 24 | $-28.7M | $102.0M | ||
| Q1 24 | $33.9M | $4.8M |
毛利率PATHRPRX
| Q4 25 | 83.3% | — | ||
| Q3 25 | 82.2% | — | ||
| Q2 25 | 82.1% | — | ||
| Q1 25 | 84.8% | — | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | 80.0% | — | ||
| Q2 24 | 83.5% | — | ||
| Q1 24 | 86.8% | — |
营业利润率PATHRPRX
| Q4 25 | 3.2% | 62.4% | ||
| Q3 25 | -5.6% | 70.1% | ||
| Q2 25 | -4.6% | 36.3% | ||
| Q1 25 | 7.9% | 94.0% | ||
| Q4 24 | -12.2% | 60.9% | ||
| Q3 24 | -32.7% | — | ||
| Q2 24 | -14.8% | 50.2% | ||
| Q1 24 | 3.7% | -13.0% |
净利率PATHRPRX
| Q4 25 | 48.4% | 34.4% | ||
| Q3 25 | 0.4% | 47.3% | ||
| Q2 25 | -6.3% | 5.2% | ||
| Q1 25 | 12.2% | 41.9% | ||
| Q4 24 | -3.0% | 35.1% | ||
| Q3 24 | -27.2% | 96.3% | ||
| Q2 24 | -8.6% | 19.0% | ||
| Q1 24 | 8.4% | 0.8% |
每股收益（稀释后）PATHRPRX
| Q4 25 | $0.37 | $0.49 | ||
| Q3 25 | $0.00 | $0.67 | ||
| Q2 25 | $-0.04 | $0.07 | ||
| Q1 25 | $0.09 | $0.55 | ||
| Q4 24 | $-0.02 | $0.46 | ||
| Q3 24 | $-0.15 | $1.21 | ||
| Q2 24 | $-0.05 | $0.23 | ||
| Q1 24 | $0.07 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.9B | $9.7B |
| 总资产 | $2.9B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PATHRPRX
| Q4 25 | $1.4B | $618.7M | ||
| Q3 25 | $1.4B | $938.9M | ||
| Q2 25 | $1.6B | $631.9M | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $929.0M | ||
| Q3 24 | $1.7B | $950.1M | ||
| Q2 24 | $1.9B | $1.8B | ||
| Q1 24 | $1.9B | $843.0M |
总债务PATHRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益PATHRPRX
| Q4 25 | $1.9B | $9.7B | ||
| Q3 25 | $1.7B | $9.6B | ||
| Q2 25 | $1.7B | $9.5B | ||
| Q1 25 | $1.8B | $9.8B | ||
| Q4 24 | $1.7B | $10.3B | ||
| Q3 24 | $1.8B | $10.3B | ||
| Q2 24 | $2.0B | $9.8B | ||
| Q1 24 | $2.0B | $9.9B |
总资产PATHRPRX
| Q4 25 | $2.9B | $19.6B | ||
| Q3 25 | $2.6B | $19.3B | ||
| Q2 25 | $2.6B | $18.3B | ||
| Q1 25 | $2.9B | $17.6B | ||
| Q4 24 | $2.7B | $18.2B | ||
| Q3 24 | $2.7B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B | ||
| Q1 24 | $3.0B | $16.1B |
负债/权益比PATHRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $25.1M | — |
| 自由现金流率自由现金流/营收 | 6.1% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.14× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PATHRPRX
| Q4 25 | $28.3M | $827.1M | ||
| Q3 25 | $41.6M | $702.6M | ||
| Q2 25 | $119.0M | $364.0M | ||
| Q1 25 | $146.1M | $596.1M | ||
| Q4 24 | $28.1M | $742.5M | ||
| Q3 24 | $46.4M | $703.6M | ||
| Q2 24 | $100.0M | $658.2M | ||
| Q1 24 | $145.6M | $664.6M |
自由现金流PATHRPRX
| Q4 25 | $25.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $106.2M | — | ||
| Q1 25 | $138.7M | — | ||
| Q4 24 | $23.2M | — | ||
| Q3 24 | $45.0M | — | ||
| Q2 24 | $98.8M | — | ||
| Q1 24 | $141.8M | — |
自由现金流率PATHRPRX
| Q4 25 | 6.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 29.8% | — | ||
| Q1 25 | 32.7% | — | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 29.5% | — | ||
| Q1 24 | 35.0% | — |
资本支出强度PATHRPRX
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.9% | — |
现金转化率PATHRPRX
| Q4 25 | 0.14× | 3.86× | ||
| Q3 25 | 26.25× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 2.82× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 4.29× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
